Gilead Sciences reports Q2 results today after the bell with the bullish options fervor from last week fading and the analyst community in a distinctly cautious mood.
The options picture has shifted since the prior note. The put/call ratio has edged back up to 0.43, essentially flat with its 20-day mean and carrying a z-score near zero. That is a meaningful change from the call-heavy extreme recorded just days ago, when the PCR touched its 52-week low of 0.40. Options traders have quietly neutralised their positioning into the actual print. The stock has also softened from last week's close of $134.32, pulling back to $131.15 — a roughly 2% retreat that partially reverses the pre-earnings lift, though the one-month change remains barely negative.
The analyst community has been trimming, not abandoning. Morgan Stanley cut its price target modestly to $165 while holding its Overweight rating, a minor tweak that preserves the bull thesis. Barclays was more pointed, lowering its target from $155 to $145 and holding at Equal-Weight — neutral at best. The sharpest move came from Leerink Partners, which downgraded to Market Perform and cut its target from $146 to $127 on July 21, putting its target below the current price. The mean Street target still sits at $157, implying roughly 20% upside from here, but the direction of recent revisions has been uniformly downward. Bulls point to Gilead's durable HIV franchise, growing oncology optionality, and a factor score for 30-day EPS momentum that ranks in the 95th percentile. Bears flag the 90-day EPS momentum score at the 10th percentile — a sign that the near-term revision cycle has improved but the broader earnings trajectory remains challenged.
Short interest carries no real signal heading in. Bears hold just over 2% of the free float — a level the previous note correctly characterised as a quiet story — and that position has barely moved. Borrow availability is essentially unlimited. The lending market is entirely uninvolved in whatever happens tonight.
The Q2 report is therefore a test of whether Gilead's near-term earnings improvement is durable enough to reverse the string of downward analyst revisions — and whether the HIV and oncology pipeline can deliver the kind of concrete update that reignites the momentum the stock lost over the past six months.
See the live data behind this article on ORTEX.
Open GILD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
